Marte Schrumpf Heiberg
Senior researcher
https://orcid.org/0000-0003-1104-7755
https://orcid.org/0000-0003-1104-7755
Education
- Doctor (MD), University of Oslo (2001)
- Specialist in rheumatology (2015)
- Doctoral degree (PhD) at the Department of Clinical Medicine, University of Oslo (2009)
Position
- Senior researcher, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
- Senior physician in rheumatology, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
Field of interest
- Rheumatology
- Arthritic diseases
- Immunotherapy
- Anti-rheumatic disease-modifying drugs
Other
- Head of the National Clinical Network in REMEDY
Telephone
visiting address
Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo
Postal address
Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo
Projects
WP1 - Optimized medical interventions
NORTH STAR
The Nordic study of strategy tests and registries for rheumatic diseases
Project Manager:
Espen A. HaavardsholmWP2 - PPhenotyping for personalized medicine
RIMRA
Rheumatic immune-related side effects in patients treated with immunotherapy
Project Manager:
Marte Schrumpf HeibergProject Manager:
Silje Watterdal SyversenPublications
Publications taken from the National Science Archive (NVA):
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial
Kristina Lend, Jon Lampa, Leonid Padyukov, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström
Annals of the Rheumatic Diseases
2024
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial
Mikkel Østergaard, Ronald F Van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström
Annals of the Rheumatic Diseases
2023
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial
Kristina Lend, Ronald F van Vollenhoven, Jon Lampa, Merete Lund Hetland, Espen A. Haavardsholm, Dan Nordström
The Lancet Rheumatology
2022
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
Marit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, Mikkel Østergaard, Till Uhlig, Marte Schrumpf
Arthritis Research & Therapy
2021
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial
Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan C. Nordström, Michael Nurmohamed, Bjorn Gudbjornsson
The BMJ
2020
Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study
Daniel Glinatsi, Marte Schrumpf, Anna Rudin, Dan C. Nordström, Espen A. Haavardsholm, Björn Gudbjörnsson
Trials
2017
The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study
Karen Minde Fagerli, Elisabeth Lie, Desirée van der Heijde, Marte S. Heiberg, Åse Lexberg, Erik Rødevand
Annals of the Rheumatic Diseases
2014